677 results match your criteria Dystonia Tardive


Dyskinesia is most centrally situated in an estimated network of extrapyramidal syndrome in Asian patients with schizophrenia: findings from research on Asian psychotropic prescription patterns for antipsychotics.

Nord J Psychiatry 2020 Jun 25:1-9. Epub 2020 Jun 25.

Department of Psychiatry and Psychobiology, Nagoya University, Graduate School of Medicine, Nagoya, Japan.

Network analysis provides a new viewpoint that explicates intertwined and interrelated symptoms into dynamic causal architectures of symptom clusters. This is a process called 'symptomics' and is concurrently applied to various areas of symptomatology. Using the data from Research on Asian Psychotropic Prescription Patterns for Antipsychotics (REAP-AP), we aimed to estimate a network model of extrapyramidal syndrome in patients with schizophrenia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/08039488.2020.1777462DOI Listing

Antidepressants and movement disorders: a postmarketing study in the world pharmacovigilance database.

BMC Psychiatry 2020 Jun 16;20(1):308. Epub 2020 Jun 16.

Service de Pharmacologie Médicale et Clinique, Centre de Pharmacovigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament, CHU de Toulouse, Faculté de Médecine, Toulouse, France.

Background: Antidepressants-induced movement disorders are rare and imperfectly known adverse drug reactions. The risk may differ between different antidepressants and antidepressants' classes. The objective of this study was to assess the putative association of each antidepressant and antidepressants' classes with movement disorders. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12888-020-02711-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7298955PMC

Tardive syndromes.

Pract Neurol 2020 Jun 2. Epub 2020 Jun 2.

Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London, UK.

Dopamine receptor-blocking antipsychotics, first introduced into clinical practice in 1952, were hailed as a panacea in the treatment of a number of psychiatric disorders. However, within 5 years, this notion was to be shattered by the recognition of both acute and chronic drug-induced movement disorders which can accompany their administration. Tardive syndromes, denoting the delayed onset of movement disorders following administration of dopamine receptor-blocking (and also other) drugs, have diverse manifestations ranging from the classic oro-bucco-lingual dyskinesia, through dystonic craniocervical and trunk posturing, to abnormal breathing patterns. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/practneurol-2020-002566DOI Listing

Treatment of Tardive Dyskinesia.

Neurol Clin 2020 05 28;38(2):379-396. Epub 2020 Feb 28.

Department of Neurology, Baylor College of Medicine, Parkinson's Disease Center and Movement Disorders Clinic, 7200 Cambridge, 9th Floor, Suite 9A, Houston, TX 77030-4202, USA. Electronic address:

Tardive dyskinesia (TD) is an iatrogenic condition that encompasses a wide phenomenological spectrum of movement disorders caused by exposure to dopamine receptor blocking agents (DRBAs). TD may cause troublesome or disabling symptoms that impair quality of life. Due to frequent, often inappropriate, use of DRBAs, TD prevalence rates among patients exposed to DRBAs continue to be high. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ncl.2020.01.004DOI Listing

Clinical Rating Scales and Quantitative Assessments of Movement Disorders.

Authors:
Arjun Tarakad

Neurol Clin 2020 05 6;38(2):231-254. Epub 2020 Feb 6.

Department of Neurology, Parkinson's Disease Center and Movement Disorders Clinic, Baylor College of Medicine, 7200 Cambridge Street Suite 9A, Houston, TX 77030, USA. Electronic address:

This article reviews scales that have been developed for, validated in, and/or frequently used across multiple movement disorders with a focus on assessment of motor and nonmotor symptoms of Parkinson disease. Rating scales used in other disease states include those for essential tremor, dystonia (generalized dystonia, cervical dystonia, and blepharospasm), Tourette syndrome, Huntington disease, tardive dyskinesia, Wilson disease, ataxia, and functional movement disorders. Key features of each scale as well as cited criticisms and limitations of each scale are also discussed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ncl.2019.12.001DOI Listing

Tardive dystonia improved with discontinuation of trazodone in an elderly schizophrenia patient: a case report.

Ann Gen Psychiatry 2020 1;19:23. Epub 2020 Apr 1.

Minamigaoka Hospital, 3-13-1 Imamachi, Kokurakita-ku, Kitakyushu, Fukuoka 8030862 Japan.

Background: Tardive dystonia associated with antidepressant use is rare and often under-recognized. We had an experience with trazodone, which is used for delirium and insomnia prescribed in general hospital, inducing tardive dystonia.

Case Presentation: A 61-year-old Japanese woman had been treated for schizophrenia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12991-020-00273-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7114810PMC

Investigation of the effects of cannabidiol on vacuous chewing movements, locomotion, oxidative stress and blood glucose in rats treated with oral haloperidol.

World J Biol Psychiatry 2020 May 5:1-15. Epub 2020 May 5.

Department of Biochemistry, Nigerian Institute of Medical Research Yaba Lagos, Lagos, Nigeria.

Tardive dyskinesia (TD) unlike acute dystonia may be irreversible. This study investigated the effects of oral cannabidiol (CBD) on haloperidol-induced vacuous chewing movement (VCM) model of TD. There were six experimental groups with different combinations of oral cannabidiol with 5 mg/kg of haloperidol given orally. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/15622975.2020.1752934DOI Listing

The dentato-rubro-thalamic tract as the potential common deep brain stimulation target for tremor of various origin: an observational case series.

Acta Neurochir (Wien) 2020 05 29;162(5):1053-1066. Epub 2020 Jan 29.

Department of Stereotactic and Functional Neurosurgery, Freiburg University Medical Center, Freiburg (i.Br.), Germany.

Introduction: Deep brain stimulation alleviates tremor of various origins. The dentato-rubro-thalamic tract (DRT) has been suspected as a common tremor-reducing structure. Statistical evidence has not been obtained. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00701-020-04248-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7156360PMC

A preliminary exome sequence in three patients with tardive dystonia.

Psychiatr Genet 2020 04;30(2):57-59

Department of Psychiatry, Chiba University Graduate School of Medicine.

Tardive dystonia is one of the most serious adverse events that can be caused by antipsychotic treatment, but few studies have examined the etiology of tardive dystonia, and no genetic study using a next-generation sequencing technique has been performed to date. We conducted exome sequencing in three subjects with severe tardive dystonia. We analyzed the results focusing on candidate genes of primary dystonia, for example, TOR1A, GCH1, TH, THAP1, and SGCE. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/YPG.0000000000000248DOI Listing

Models of hyperkinetic disorders in primates.

Authors:
Erwan Bezard

J Neurosci Methods 2020 Feb 16;332:108551. Epub 2019 Dec 16.

Univ. de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, F-33000 Bordeaux, France; CNRS, Institut des Maladies Neurodégénératives, UMR 5293, F-33000 Bordeaux, France. Electronic address:

Hyperkinetic movement disorders include tremors, dystonia, chorea, tics, myoclonus, stereotypies, restless legs syndrome, and various other disorders with abnormal involuntary movements. Although several disorders could be included in such a broad spectrum, a limited number of conditions are modeled in non-human primates. These disabling conditions include notably L-dopa-induced dyskinesia in Parkinson's disease, tardive dyskinesia, essential tremor and Huntington's disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jneumeth.2019.108551DOI Listing
February 2020

Quality of life outcomes after deep brain stimulation in dystonia: A systematic review.

Parkinsonism Relat Disord 2020 01 18;70:82-93. Epub 2019 Nov 18.

Department of Neurology, Norman Fixel Institute for Neurological Diseases, University of Florida, Gainesville, FL, USA.

Dystonia is an incurable movement disorder which can cause not only physical but also mental problems, leading to impaired health-related quality of life (HRQoL). For patients with dystonia refractory to medical treatment, deep brain stimulation (DBS) is a well-established surgical treatment. The objective of this systematic review is to provide a better understanding of HRQoL outcomes after DBS for dystonia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.parkreldis.2019.11.016DOI Listing
January 2020

The psychopharmacology of catatonia, neuroleptic malignant syndrome, akathisia, tardive dyskinesia, and dystonia.

Handb Clin Neurol 2019 ;165:415-428

Department of Psychiatry and Institute for Health and Care Research, VU University Medical Centre, Amsterdam, The Netherlands.

Although highly prevalent, motor syndromes in psychiatry and motor side effects of psychopharmacologic agents remain understudied. Catatonia is a syndrome with specific motor abnormalities that can be seen in the context of a variety of psychiatric and somatic conditions. The neuroleptic malignant syndrome is a lethal variant, induced by antipsychotic drugs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/B978-0-444-64012-3.00025-3DOI Listing

Long-Term Response to Clozapine and Its Clinical Correlates in the Treatment of Tardive Movement Syndromes: A Naturalistic Observational Study in Patients With Psychotic Disorders.

J Clin Psychopharmacol 2019 Nov/Dec;39(6):591-596

From the Department of Psychiatry, Sungkyunkwan University School of Medicine, Samsung Medical Center.

Purpose: Given that switching to clozapine is an important treatment option for tardive movement syndrome (TMS), its effect and clinical correlates have not been fully explored yet. This study investigated the improvement of TMS after switching to clozapine and factors associated with the response in a naturalistic outpatient setting.

Methods: Subjects were 35 patients with schizophrenia or bipolar disorder receiving only clozapine as an antipsychotic drug for more than 12 months. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JCP.0000000000001114DOI Listing

Clinical outcomes of pallidal deep brain stimulation for dystonia implanted using intraoperative MRI.

J Neurosurg 2019 Oct 11:1-13. Epub 2019 Oct 11.

Departments of1Neurology and.

Objective: Lead placement for deep brain stimulation (DBS) using intraoperative MRI (iMRI) relies solely on real-time intraoperative neuroimaging to guide electrode placement, without microelectrode recording (MER) or electrical stimulation. There is limited information, however, on outcomes after iMRI-guided DBS for dystonia. The authors evaluated clinical outcomes and targeting accuracy in patients with dystonia who underwent lead placement using an iMRI targeting platform. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3171/2019.6.JNS19548DOI Listing
October 2019
2 Reads

Lurasidone-Induced Tardive Syndrome.

Mov Disord Clin Pract 2019 Sep 24;6(7):601-604. Epub 2019 Jul 24.

Department of Neurology Emory University School of Medicine Atlanta Georgia USA.

Introduction: Tardive syndrome (TS) is an often irreversible movement disorder caused by dopamine receptor-blocking agents (DRBAs). Although TS are well recognized to occur with typical antipsychotics, less well appreciated is that atypical antipsychotics also carry a risk of TS.

Methods: Case series. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mdc3.12812DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6749798PMC
September 2019
4 Reads

Recognizing Movement Disorder Emergencies - A Practical Review For Non-Neurologist.

J Ayub Med Coll Abbottabad 2019 Jul-Sep;31(3):448-453

Department of Neurological Sciences, University of Nebraska Medical Center, Omaha, NE, United States.

Neurology still remains one of the most underserved specialties of medicine in Pakistan with roughly one neurologist per million people. Movement disorders (MD) are neurological problems that interfere with patient's motor abilities and diagnosis is typically clinical. In this review, we describe a practical approach to common MD emergencies that may be encountered by a non-neurologist physician, emphasizing on formulating a working diagnosis and their immediate management. Read More

View Article

Download full-text PDF

Source
December 2019
4 Reads

Refractory Open Jaw Oromandibular Tardive Dystonia with a Sensory Trick, Treated with Botulinum Toxin: A Case Report.

Neurol India 2019 Jul-Aug;67(4):1110-1111

Department of Neurology, Faculty of Medicine, Ain Shams University, Cairo, Egypt.

Jaw-opening oromandibular dystonia (O-OMD) is a clinical subtype of OMD, commonly resistant to treatment. Here, we report a distinct case of tardive O-OMD with a characteristic sensory trick, successfully treated with high-dose botulinum toxin (BTX) injection. A 34-year-old male patient presented with involuntary jaw opening, tongue protrusion, dysarthria, and mild cervical dystonia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/0028-3886.266235DOI Listing
March 2020
2 Reads
1.084 Impact Factor

Analyzing Nanotheraputics-Based Approaches for the Management of Psychotic Disorders.

J Pharm Sci 2019 12 6;108(12):3757-3768. Epub 2019 Sep 6.

Department of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi 110062, India. Electronic address:

Psychoses are brain disorders clinically manifested by cognitive conditions such as hallucinations, delirium, dementia, schizophrenia, and delusions. Antipsychotic drugs are associated with significant side effects such as dystonia, tardive dyskinesia, involuntary muscle movement, and metabolic disorders. Moreover, those antipsychotics currently available have poor bioavailability, drug-related adverse effects, poor therapeutic efficacy, and poor brain delivery resulting from the blood-brain barrier. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.xphs.2019.08.027DOI Listing
December 2019
5 Reads

A Possible Case of Escitalopram-Induced Tardive Dystonia.

Psychosomatics 2020 Mar - Apr;61(2):188-192. Epub 2019 Jul 3.

Department of Psychiatry, Dartmouth College Geisel School of Medicine, Hanover, NH; Department of Psychiatry, Dartmouth-Hitchcock Medical Center, Lebanon, NH.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.psym.2019.06.004DOI Listing
July 2019
4 Reads

Tongue Protrusion Dystonia in Pantothenate Kinase-Associated Neurodegeneration.

Pediatr Neurol 2020 02 13;103:76-78. Epub 2019 Jun 13.

Department of Neurology, Hazrat Rasool Hospital, Iran University of Medical Sciences, Tehran, Iran. Electronic address:

Background: Tongue protrusion dystonia is an uncommon focal dystonia involving the lingual muscles. Causes of tongue protrusion dystonia include tardive dystonia, posthypoxic dystonia, neuroacanthocytosis, pantothenate kinase-associated neurodegeneration, and Lesch-Nyhan syndrome.

Method: We summarize three children with pantothenate kinase-associated neurodegeneration and tongue protrusion dystonia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pediatrneurol.2019.06.004DOI Listing
February 2020
8 Reads

Long-term safety and efficacy of deutetrabenazine for the treatment of tardive dyskinesia.

J Neurol Neurosurg Psychiatry 2019 12 10;90(12):1317-1323. Epub 2019 Jul 10.

Georgetown University, Washington, District of Columbia, USA.

Objective: To evaluate the long-term safety and efficacy of deutetrabenazine in patients with tardive dyskinesia (TD).

Method: Patients with TD who completed the 12 week, phase 3, placebo-controlled trials were eligible to enter this open-label, single-arm study. The open-label study consisted of a 6 week dose-escalation phase and a long-term maintenance phase (clinic visits at Weeks 4, 6 and 15, and every 13 weeks until Week 106). Read More

View Article

Download full-text PDF

Source
http://jnnp.bmj.com/lookup/doi/10.1136/jnnp-2018-319918
Publisher Site
http://dx.doi.org/10.1136/jnnp-2018-319918DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6902058PMC
December 2019
26 Reads

Characteristics of Patients Experiencing Extrapyramidal Symptoms or Other Movement Disorders Related to Dopamine Receptor Blocking Agent Therapy.

J Clin Psychopharmacol 2019 Jul/Aug;39(4):336-343

Department of Psychiatry, Community Health Network, Indianapolis, IN.

Purpose/background: Dopamine receptor blocking agents (DRBAs), also known as antipsychotics, are medications widely used to treat a growing number of mental health diagnoses. However, their utility is limited by the potential to cause serious adverse movement reactions. Akathisia, dystonia, parkinsonism, and tardive dyskinesia (collectively known as extrapyramidal symptoms or EPSs) are associated with reduced social and occupational functioning, negative patient attitudes toward treatment, and nonadherence to pharmacotherapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JCP.0000000000001061DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6594730PMC
February 2020
20 Reads

[Neurosurgical treatment of dystonia].

Ugeskr Laeger 2019 May;181(20)

In this review, we present evidence of treatment effect with deep brain stimulation (DBS) in patients with isolated forms of dystonia with generalised-, segmental- and focal phenotypes as well as tardive dystonia and dyskinetic cerebral palsy. Dystonia is a heterogeneous movement disorder, which can be disabling and difficult to treat. Patients with dystonia, who do not experience relief with medication and botulinum toxin, may be candidates for DBS. Read More

View Article

Download full-text PDF

Source
May 2019
3 Reads

Dystonia and Parkinson's disease: What is the relationship?

Neurobiol Dis 2019 12 9;132:104462. Epub 2019 May 9.

Edmond J. Safra Program in Parkinson's Disease and the Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, University of Toronto, Toronto, Canada. Electronic address:

Dystonia and Parkinson's disease are closely linked disorders sharing many pathophysiological overlaps. Dystonia can be seen in 30% or more of the patients suffering with PD and sometimes can precede the overt parkinsonism. The response of early dystonia to the introduction of dopamine replacement therapy (levodopa, dopamine agonists) is variable; dystonia commonly occurs in PD patients following levodopa initiation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.nbd.2019.05.001DOI Listing
December 2019
6 Reads

Drug-induced movement disorders.

Aust Prescr 2019 Apr 1;42(2):56-61. Epub 2019 Apr 1.

Movement Disorders Unit, Department of Neurology, Westmead Hospital, Sydney.

Many Therapeutic And Illicit Drugs Can Cause Movement Disorders Antipsychotics And Antiemetics Are Most Commonly Implicated:

The Time Of Onset Of The Movement Disorder May Be Acute Subacute Or Chronic The Severity Can Range From Mild To Severe And Life-threatening:

Early Recognition Of A Drug-induced Movement Disorder Is Essential To Allow For Prompt Intervention This Includes Stopping The Offending Drug Supportive Care And Sometimes Other Pharmacological Treatment: Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18773/austprescr.2019.014DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6478951PMC
April 2019
9 Reads

Gnal haploinsufficiency causes genomic instability and increased sensitivity to haloperidol.

Exp Neurol 2019 08 26;318:61-70. Epub 2019 Apr 26.

Department of Psychology, University of Memphis, Memphis, TN 38152, USA. Electronic address:

GNAL encodes guanine nucleotide-binding protein subunit Gα(olf) which plays a key role in striatal medium spiny neuron (MSN)-dopamine signaling. GNAL loss-of-function mutations are causally-associated with isolated dystonia, a movement disorder characterized by involuntary muscle contractions leading to abnormal postures. Dopamine D2 receptor (D2R) blockers such as haloperidol are mainstays in the treatment of psychosis but may contribute to the development of secondary acute and tardive dystonia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.expneurol.2019.04.014DOI Listing
August 2019
9 Reads

Response to Letter to the Editor.

Tremor Other Hyperkinet Mov (N Y) 2019 6;9:630. Epub 2019 Feb 6.

Department of Neurology, Butler Hospital, Warren Alpert Medical School of Brown University, Providence, RI, US.

In Response To: Walker RH. Reply to: Tardive dyskinesia-like syndrome due to drugs that do not block dopamine receptors: rare or non-existent: literature review. Tremor Other Hyperkinet Mov. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7916/0rjw-cv10DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6377913PMC
March 2019
25 Reads

Reply to: Tardive Dyskinesia-like Syndrome Due to Drugs that do not Block Dopamine Receptors: Rare or Non-existent: Literature Review.

Authors:
Ruth H Walker

Tremor Other Hyperkinet Mov (N Y) 2019 13;9:626. Epub 2019 Feb 13.

Department of Neurology, James J. Peters Veterans Affairs Medical Center, Bronx, New York, NY, US.

In Response To: D'Abreu A, Friedman JH. Tardive dyskinesia-like syndrome due to drugs that do not block dopamine receptors: rare or non-existent: literature review. Tremor Other Hyperkinet Mov. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7916/3rez-p096DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6377912PMC
March 2019
7 Reads

Antipsychotics for patients with pain.

Korean J Pain 2019 Jan 2;32(1):3-11. Epub 2019 Jan 2.

Department of Anesthesia and Pain Medicine, Pusan National University, Busan, Korea.

Going back to basics prior to mentioning the use of antipsychotics in patients with pain, the International Association for the Study of Pain (IASP) definition of pain can be summarized as an unpleasant experience, composed of sensory experience caused by actual tissue damage and/or emotional experience caused by potential tissue damage. Less used than antidepressants, antipsychotics have also been used for treating this unpleasant experience as adjuvant analgesics without sufficient evidence from research. Because recently developed atypical antipsychotics reduce the adverse reactions of extrapyramidal symptoms, such as acute dystonia, pseudo-parkinsonism, akathisia, and tardive dyskinesia caused by typical antipsychotics, they are expected to be used more frequently in various painful conditions, while increasing the risk of metabolic syndromes (weight gain, diabetes, and dyslipidemia). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3344/kjp.2019.32.1.3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6333575PMC
January 2019
25 Reads

A Case of Pseudodystonia in a Patient on Neuroleptics.

Mov Disord Clin Pract 2018 Sep-Oct;5(5):557-558. Epub 2018 Jul 19.

Department of Neurology-neurophysiology IBN Rochd University Health Center, Casablanca, Morocco; Faculty of Medicine and Pharmacy of Casablanca Morocco.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mdc3.12638DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6207121PMC
July 2018
7 Reads

Setting the record straight: The nosology of tardive syndromes.

Parkinsonism Relat Disord 2019 02 28;59:146-150. Epub 2018 Nov 28.

Department of Neurology, Loma Linda University Medical Center, Loma Linda, CA, USA.

We propose the use of the term tardive dyskinesia to refer to the original description of repetitive and complex oral-buccal-lingual (OBL) movements and the analogous repetitive movements of the limbs, trunk, or pelvis. The term tardive syndrome is an umbrella term to be used to refer to the spectrum of all persistent hyperkinetic, hypokinetic, and sensory phenomenologies resulting from chronic dopamine receptor blocking agent (DRBA) exposure. TD is a type of TS. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S13538020183052
Publisher Site
http://dx.doi.org/10.1016/j.parkreldis.2018.11.025DOI Listing
February 2019
9 Reads

Staged bilateral pallidotomy for dystonic camptocormia: case report.

J Neurosurg 2018 10;131(3):839-842

Camptocormia is a rare, involuntary movement disorder, presenting as truncal flexion while standing or walking, and is mainly observed as a feature of Parkinson's disease (PD) and primary dystonia. Deep brain stimulation (DBS) of the globus pallidus internus is effective for refractory camptocormia observed with PD or dystonia. However, the effectiveness of pallidotomy for camptocormia has not been investigated. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3171/2018.5.JNS1840DOI Listing
October 2018
56 Reads

Interdisciplinary recognizing and managing of drug-induced tardive oromandibular dystonia: two case reports.

Clin Case Rep 2018 Nov 26;6(11):2150-2155. Epub 2018 Sep 26.

Department of Neurology and Clinical Neurophysiology (Dystonia Clinic) Bispebjerg University Hospital University of Copenhagen Copenhagen Denmark.

Tardive dystonia is a risk factor in medical antipsychotic treatment. It often begins with repetitive involuntary jaw and tongue movements resulting in impaired chewing and detrimental effect on the dentition. The orofacial dysfunction may go unrecognized in a neurological setting. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ccr3.1548DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6230632PMC
November 2018
7 Reads

A probable case of movement disorder (Tardive dyskinesia) due to duloxetine treatment.

Agri 2018 Oct;30(4):199-201

Department of Anesthesiology and Reanimation, Zile State Hospital, Tokat, Turkey.

Tardive dyskinesia and tardive dystonia are caused by dopamine receptor blocking agents, mostly antipsychotics and sometimes antidepressants or calcium channel blockers. Duloxetine is a serotonin-noradrenaline reuptake inhibitor used in the treatment of diabetic neuropathic pain and fibromyalgia, as well as major depression. In this case, we aimed to discuss the tardive dyskinesia-like appearance of a patient using duloxetine due to fibromyalgia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5505/agri.2018.60134DOI Listing
October 2018
51 Reads

Neurostimulation in tardive dystonia/dyskinesia: A delayed start, sham stimulation-controlled randomized trial.

Brain Stimul 2018 Nov - Dec;11(6):1368-1377. Epub 2018 Sep 11.

Department of Neurology and Neurosurgery, Heinrich-Heine-University, Düsseldorf, Germany.

Introduction: Growing evidence suggests that pallidal deep brain stimulation represents a potential new therapeutic avenue in tardive dystonia/dyskinesia, but controlled and blinded randomized studies (RCT) are missing. The present RCT compares dystonia/dyskinesia severity of pallidal neurostimulation in patients with tardive dystonia using a delayed-start design paradigm.

Methods: Dystonia/dyskinesia severity was assessed via blinded videos following pallidal neurostimulation at 3 (blinded phase) and 6 months (open extension phase). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.brs.2018.08.006DOI Listing
May 2019
14 Reads

Potential Therapeutic Application for Nicotinic Receptor Drugs in Movement Disorders.

Nicotine Tob Res 2019 02;21(3):357-369

Center for Health Sciences, SRI International, Menlo Park, CA.

Emerging studies indicate that striatal cholinergic interneurons play an important role in synaptic plasticity and motor control under normal physiological conditions, while their disruption may lead to movement disorders. Here we discuss the involvement of the cholinergic system in motor dysfunction, with a focus on the role of the nicotinic cholinergic system in Parkinson's disease and drug-induced dyskinesias. Evidence for a role for the striatal nicotinic cholinergic system stems from studies showing that administration of nicotine or nicotinic receptor drugs protects against nigrostriatal degeneration and decreases L-dopa-induced dyskinesias. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ntr/nty063DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6379038PMC
February 2019
31 Reads
3.296 Impact Factor

Tardive Myoclonic Dyskinesia Responsive to Sodium Oxybate.

Clin Neuropharmacol 2018 Sep/Oct;41(5):194-196

Clinical Neurology Unit I, Department of Medicine, San Paolo University Hospital ASST Santi Paolo e Carlo.

Hyperkinetic movement disorders may be difficult to treat, but cases where patients respond to alcohol and/or drugs with similar effects have been described. We report the case of a 64-year-old man with tardive dyskinesia characterized by severe uncontrolled dystonic and myoclonic jerks of the face, shoulders, and arm and forearm muscles, which improved with oral sodium oxybate. Our case suggests the possibility to test sodium oxybate in patients with severe, drug-resistant hyperkinetic syndromes, especially when they are known to improve with alcohol. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/WNF.0000000000000290DOI Listing
December 2018
37 Reads

Movement Disorders Associated With Antipsychotic Medication in People With Schizophrenia: An Overview of Cochrane Reviews and Meta-Analysis.

Can J Psychiatry 2018 Jan 1:706743718777392. Epub 2018 Jan 1.

1 Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada.

Movement disorders associated with antipsychotic medications are relatively common, stigmatising, and potentially disabling. Their prevalence in people with psychosis who are prescribed second-generation antipsychotics (SGAs) is uncertain, as is their level of recognition by clinicinas. We conducted meta-analyses of randomised controlled trials included in the Cochrane Database of Systematic Reviews on schizophrenia and schizophrenia-like psychoses to estimate the prevalence of new-onset dystonia, akathisia, parkinsonism, and tremor with SGAs (amisulpride, asenapine, aripiprazole, clozapine, olanzapine, paliperidone, quetiapine, risperidone, L-sulpiride, and ziprasidone) approved in Canada and the UK, comparing them with haloperidol and chlorpromazine. Read More

View Article

Download full-text PDF

Source
http://journals.sagepub.com/doi/10.1177/0706743718777392
Publisher Site
http://dx.doi.org/10.1177/0706743718777392DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6299187PMC
January 2018
24 Reads

Antipsychotic-Induced Pisa Syndrome: A 2-Year Follow-up Study.

Authors:
Yen-Feng Lee

Clin Neuropharmacol 2018 Mar/Apr;41(2):60-63

Objectives: Pisa syndrome is characterized by lateral trunk flexion. It is an uncommon adverse drug reaction in patients on antipsychotic medication. Although Pisa syndrome has been reported in patients on antipsychotic treatment, previous studies have not discussed the prognosis of patients with Pisa syndrome. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/WNF.0000000000000274DOI Listing
November 2018
15 Reads

Tardive syndromes.

J Neurol Sci 2018 06 5;389:35-42. Epub 2018 Feb 5.

Parkinson's Disease and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, TX, United States. Electronic address:

Tardive syndromes are a group of hyperkinetic and hypokinetic movement disorders that occur after some delay following exposure to dopamine receptor blocking agents such as antipsychotic and anti-emetic drugs. The severity of these disorders ranges from mild to disabling or even life-threatening. There is a wide range of recognized tardive phenomenologies that may occur in isolation or in combination with each other. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jns.2018.02.005DOI Listing
June 2018
9 Reads

Asymmetric Drug-Induced Parkinsonism and Psychopathology: A Prospective Naturalistic Study in Long-Stay Psychiatric Patients.

Front Psychiatry 2018 5;9:18. Epub 2018 Feb 5.

Psychiatric Center GGz Centraal, Amersfoort, Netherlands.

Background: Drug-induced parkinsonism (DIP) is the most common movement disorder induced by antipsychotics. Although DIP is mostly symmetric, asymmetric DIP is reported in a substantial part of the patients. We investigated the frequency of motor asymmetry in DIP and its relationship to the severity of psychopathology in long-stay psychiatric patients. Read More

View Article

Download full-text PDF

Source
http://journal.frontiersin.org/article/10.3389/fpsyt.2018.00
Publisher Site
http://dx.doi.org/10.3389/fpsyt.2018.00018DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5807329PMC
February 2018
30 Reads

Historical perspectives on tardive dyskinesia.

J Neurol Sci 2018 06 3;389:4-9. Epub 2018 Feb 3.

University of Edinburgh, The Royal Edinburgh Hospital, Edinburgh EH10 5HF, Scotland, UK. Electronic address:

Tardive dyskinesia (TD) is a persistent hyperkinetic movement disorder associated with dopamine receptor blocking agents including antipsychotic medications. Although uncertainty and concern about this drug side effect have vacillated since its initial recognition 60 years ago, recent commercial interest in developing effective treatments has rekindled scientific and clinical interest after a protracted period of neglect. Although substantial research has advanced knowledge of the clinical features and epidemiology of TD, many fundamental questions raised by early investigators remain unresolved. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jns.2018.02.015DOI Listing
June 2018
15 Reads

Updating the recommendations for treatment of tardive syndromes: A systematic review of new evidence and practical treatment algorithm.

J Neurol Sci 2018 06 5;389:67-75. Epub 2018 Feb 5.

Department of Neurology, Columbia University Medical Center, New York, USA.

Background: Management of tardive syndromes (TS) is challenging, with only a few evidence-based therapeutic algorithms reported in the American Academy of Neurology (AAN) guideline in 2013.

Objective: To update the evidence-based recommendations and provide a practical treatment algorithm for management of TS by addressing 5 questions: 1) Is withdrawal of dopamine receptor blocking agents (DRBAs) an effective TS treatment? 2) Does switching from typical to atypical DRBAs reduce TS symptoms? 3) What is the efficacy of pharmacologic agents in treating TS? 4) Do patients with TS benefit from chemodenervation with botulinum toxin? 5) Do patients with TS benefit from surgical therapy?

Methods: Systematic reviews were conducted by searching PsycINFO, Ovid MEDLINE, PubMed, EMBASE, Web of Science and Cochrane for articles published between 2012 and 2017 to identify new evidence published after the 2013 AAN guidelines. Articles were classified according to an AAN 4-tiered evidence-rating scheme. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jns.2018.02.010DOI Listing
June 2018
33 Reads
2.470 Impact Factor

The nosology of tardive syndromes.

J Neurol Sci 2018 06 6;389:10-16. Epub 2018 Feb 6.

Parkinson's Disease and Movement Disorders Center, Departments of Neurology, Molecular Pharmacology and Physiology, University of South Florida, Tampa, FL 33613, United States.

Since the original description of side effects of neuroleptics, different terminologies and definitions for tardive dyskinesia (TD) and tardive syndrome (TS) have been used by different authors, and often these two terms have been used interchangeably. This paper proposes a nosology designed to define and clarify various terms and phenomenologies within the TS spectrum. We propose to use the term tardive dyskinesia to refer to the original description of repetitive and complex oral-buccal-lingual (OBL) movements, as well as to the analogous repetitive movements that can appear in the limbs, trunk, or pelvis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jns.2018.02.008DOI Listing
June 2018
77 Reads

Deep brain stimulation for tardive syndromes: Systematic review and meta-analysis.

J Neurol Sci 2018 06 5;389:55-60. Epub 2018 Feb 5.

Department of Neurology, Universitätsklinikum Schleswig-Holstein, Kiel Campus, Germany; Christian-Albrechts Universität, Kiel, Germany. Electronic address:

Among the broad entity of tardive syndromes, tardive dystonia and classical tardive dyskinesia sometimes require advanced treatments like deep brain stimulation of the globus pallidus internum (Gpi-DBS) or the subthalamic nucleus (STN-DBS). This systematic review has analyzed the currently available literature reporting cases with either tardive dystonia or dyskinesia treated with DBS. The key words for the literature search included all tardive syndromes and "deep brain stimulation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jns.2018.02.013DOI Listing
June 2018
12 Reads

Acute Cervical Dystonia Induced by Clebopride.

Case Rep Neurol Med 2017 28;2017:2834349. Epub 2017 Nov 28.

Department of Neurology, Yonsei University Wonju College of Medicine, Wonju, Republic of Korea.

Antidopaminergic drugs are known to induce extrapyramidal symptoms. Clebopride, a dopamine antagonist, also can produce parkinsonism, tardive dyskinesia, tardive dystonia, hemifacial dystonia, or oculogyric crisis; however, acute dystonic reaction caused by clebopride has not been reported in adults. We report two young men who experienced acute cervical dystonia within a few days of taking clebopride. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2017/2834349DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5733119PMC
November 2017
33 Reads

Patient Evaluation and Selection for Movement Disorders Surgery: The Changing Spectrum of Indications.

Prog Neurol Surg 2018 12;33:80-93. Epub 2018 Jan 12.

This report summarizes the state-of-the-art and controversies around patient selection for deep brain stimulation (DBS) for various conditions. Parkinson's disease (PD): several class I studies have shown superiority of DBS over best medical treatment for advanced PD with fluctuations and further inclusion criteria. One class I study suggests that PD patients with early motor complications might gain more quality of life if operated within 3 years after the onset of fluctuations. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000480910DOI Listing
August 2018
17 Reads

Clinical and Phenomenological Characteristics of Patients with Task-Specific Lingual Dystonia: Possible Association with Occupation.

Authors:
Kazuya Yoshida

Front Neurol 2017 11;8:649. Epub 2017 Dec 11.

Department of Oral and Maxillofacial Surgery, National Hospital Organization, Kyoto Medical Center, Kyoto, Japan.

Background: Lingual dystonia is a subtype of oromandibular dystonia, which is a movement disorder characterized by involuntary sustained or intermittent contraction of the masticatory and/or tongue muscles. Lingual dystonia interferes with important daily activities, such as speaking, chewing, and swallowing, resulting in vocational and social disability.

Objective: The aim of this study was to investigate a possible relationship between occupation and the development of lingual dystonia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fneur.2017.00649DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5732148PMC
December 2017
21 Reads